Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer
Abstract Background Recent study showed that individuals with type 2 diabetes have a high risk of developing colorectal cancer (CRC), in which Receptor for Advanced Glycation End Products (RAGE) plays a pivotal role. We conducted a cross-sectional study to examine the relationships of circulating sR...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-11-01
|
| Series: | BMC Endocrine Disorders |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12902-020-00647-9 |
| _version_ | 1818262757480333312 |
|---|---|
| author | Xiaohai Zhou Ning Lin Mingjie Zhang Xiaoling Wang Ye An Qing Su Peng Du Bo Li Hanbei Chen |
| author_facet | Xiaohai Zhou Ning Lin Mingjie Zhang Xiaoling Wang Ye An Qing Su Peng Du Bo Li Hanbei Chen |
| author_sort | Xiaohai Zhou |
| collection | DOAJ |
| description | Abstract Background Recent study showed that individuals with type 2 diabetes have a high risk of developing colorectal cancer (CRC), in which Receptor for Advanced Glycation End Products (RAGE) plays a pivotal role. We conducted a cross-sectional study to examine the relationships of circulating sRAGE, CRC and other clinical factors in type2 diabetes patients. Methods A total of 150 type 2 diabetes patients aged 50 years and older were enrolled, including 50 patients with CRC and 100 patients without CRC. We measured Serum levels of sRAGE and interleukin-6(IL-6) using an enzyme-linked immunosorbent assay (ELISA). In addition, other clinical parameters were also measured during hospitalization. Results Type 2 diabetes patients with CRC had higher triglyceride, total cholesterol, IL-6, and circulating sRAGE levels and lower use of medicines than type 2 diabetes patients without CRC. Circulating sRAGE was associated with an increased risk for CRC (OR = 2.289 for each SD increase in sRAGE, 95% CI = 1.037–5.051; P = 0.04) among Type 2 diabetes patients after adjustment for confounders. Furthermore, circulating sRAGE levels among type 2 diabetes patients were positively correlated with triglyceride (r = 0.377, P < 0.001), total cholesterol (r = 0.491, P < 0.001), and low-density lipoprotein cholesterol (LDL-c)(r = 0.330, P < 0.001) levels; the homeostatic model assessment for insulin resistance(HOMA-IR)score (r = 0.194, P = 0.017); and fasting serum insulin (r = 0.167, P = 0.041) and IL-6 (r = 0.311, P < 0.001) concentrations. Conclusions Our results suggested that circulating sRAGE is independently risk factor for CRC, and also closely related to inflammation, dyslipidemia in type 2 diabetes patients. |
| first_indexed | 2024-12-12T19:08:12Z |
| format | Article |
| id | doaj.art-88e1772bd9c442d2be199cf2309a111a |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-12-12T19:08:12Z |
| publishDate | 2020-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-88e1772bd9c442d2be199cf2309a111a2022-12-22T00:14:55ZengBMCBMC Endocrine Disorders1472-68232020-11-012011710.1186/s12902-020-00647-9Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancerXiaohai Zhou0Ning Lin1Mingjie Zhang2Xiaoling Wang3Ye An4Qing Su5Peng Du6Bo Li7Hanbei Chen8Department of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineShanghai Jiahui International HospitalDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Colorectal Surgery, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineDepartment of Endocrinology, Xinhua Hospital affiliated with Shanghai Jiaotong University School of MedicineAbstract Background Recent study showed that individuals with type 2 diabetes have a high risk of developing colorectal cancer (CRC), in which Receptor for Advanced Glycation End Products (RAGE) plays a pivotal role. We conducted a cross-sectional study to examine the relationships of circulating sRAGE, CRC and other clinical factors in type2 diabetes patients. Methods A total of 150 type 2 diabetes patients aged 50 years and older were enrolled, including 50 patients with CRC and 100 patients without CRC. We measured Serum levels of sRAGE and interleukin-6(IL-6) using an enzyme-linked immunosorbent assay (ELISA). In addition, other clinical parameters were also measured during hospitalization. Results Type 2 diabetes patients with CRC had higher triglyceride, total cholesterol, IL-6, and circulating sRAGE levels and lower use of medicines than type 2 diabetes patients without CRC. Circulating sRAGE was associated with an increased risk for CRC (OR = 2.289 for each SD increase in sRAGE, 95% CI = 1.037–5.051; P = 0.04) among Type 2 diabetes patients after adjustment for confounders. Furthermore, circulating sRAGE levels among type 2 diabetes patients were positively correlated with triglyceride (r = 0.377, P < 0.001), total cholesterol (r = 0.491, P < 0.001), and low-density lipoprotein cholesterol (LDL-c)(r = 0.330, P < 0.001) levels; the homeostatic model assessment for insulin resistance(HOMA-IR)score (r = 0.194, P = 0.017); and fasting serum insulin (r = 0.167, P = 0.041) and IL-6 (r = 0.311, P < 0.001) concentrations. Conclusions Our results suggested that circulating sRAGE is independently risk factor for CRC, and also closely related to inflammation, dyslipidemia in type 2 diabetes patients.http://link.springer.com/article/10.1186/s12902-020-00647-9Type 2 diabetesColorectal CancerSoluble receptor for advanced glycation end-products |
| spellingShingle | Xiaohai Zhou Ning Lin Mingjie Zhang Xiaoling Wang Ye An Qing Su Peng Du Bo Li Hanbei Chen Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer BMC Endocrine Disorders Type 2 diabetes Colorectal Cancer Soluble receptor for advanced glycation end-products |
| title | Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| title_full | Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| title_fullStr | Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| title_full_unstemmed | Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| title_short | Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| title_sort | circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer |
| topic | Type 2 diabetes Colorectal Cancer Soluble receptor for advanced glycation end-products |
| url | http://link.springer.com/article/10.1186/s12902-020-00647-9 |
| work_keys_str_mv | AT xiaohaizhou circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT ninglin circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT mingjiezhang circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT xiaolingwang circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT yean circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT qingsu circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT pengdu circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT boli circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer AT hanbeichen circulatingsolublereceptorforadvancedglycationendproductsandotherfactorsintype2diabetespatientswithcolorectalcancer |